301 related articles for article (PubMed ID: 35512998)
1.
Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
5. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
6. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416
[TBL] [Abstract][Full Text] [Related]
7.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
8. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
[TBL] [Abstract][Full Text] [Related]
9. Lesion detection by [
Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhu P; Wang Y; Zhang W; Liu X
Medicine (Baltimore); 2021 Jan; 100(4):e24339. PubMed ID: 33530227
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
12. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
13. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
14. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of
Togo M; Yokobori T; Shimizu K; Handa T; Kaira K; Sano T; Tsukagoshi M; Higuchi T; Yokoo S; Shirabe K; Oyama T
Br J Cancer; 2020 May; 122(11):1686-1694. PubMed ID: 32238919
[TBL] [Abstract][Full Text] [Related]
16. Study of
Niemeijer AN; Oprea-Lager DE; Huisman MC; Hoekstra OS; Boellaard R; de Wit-van der Veen BJ; Bahce I; Vugts DJ; van Dongen GAMS; Thunnissen E; Smit EF; de Langen AJ
J Nucl Med; 2022 Mar; 63(3):362-367. PubMed ID: 34272316
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of
Ha SC; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY
Acta Otolaryngol; 2019 Sep; 139(9):810-815. PubMed ID: 31274365
[No Abstract] [Full Text] [Related]
20. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
